Novartis Lung cancer drug Canakinumab fails in Phase 3 trial Ruchika Sharma17 Aug 2022 4:15 PM ISTBasel: Novartis has recently announced that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of...
Setback: Novartis lung cancer drug fails phase 3 study CANOPY-1 Ruchika Sharma26 Oct 2021 10:00 AM ISTBasel: Novartis has announced that the CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints of overall...
Canakinumab does not improve survival in severe COVID-19 finds JAMA study Dr Satabdi Saha22 July 2021 8:25 AM ISTAmong patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood...
Setback: Novartis arthritis drug Canakinumab fails to help Covid patients Ruchika Sharma8 Nov 2020 11:00 AM ISTZurich: Novartis's canakinumab failed to help Covid-19 patients survive without invasive ventilation compared with standard therapy, the Swiss...
Canakinumab shows promise for treatment of large joint osteoarthritis Hina Zahid4 Aug 2020 9:45 AM ISTAn exploratory analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) randomized double-blind, placebo-controlled...
